Antithrombotic Reversal Agents

Matthew D Wilson; Jonathan E Davis

doi:10.1016/j.hoc.2017.08.013

Antithrombotic Reversal Agents

Hematol Oncol Clin North Am. 2017 Dec;31(6):1147-1157. doi: 10.1016/j.hoc.2017.08.013.

Authors

Matthew D Wilson¹, Jonathan E Davis²

Affiliations

¹ Department of Emergency Medicine, Georgetown University Hospital, Washington Hospital Center, 110 Irving Street, NA 1177, Washington, DC 20010, USA.
² Department of Emergency Medicine, Georgetown University Hospital, Washington Hospital Center, 110 Irving Street, NA 1177, Washington, DC 20010, USA. Electronic address: jdthere@gmail.com.

PMID: 29078928
DOI: 10.1016/j.hoc.2017.08.013

Abstract

The actively bleeding anticoagulated patient presenting to the emergency department requires rapid evaluation and treatment, which is made increasingly complicated by the ever-evolving antithrombotic treatment options used in medicine. Even with excellent supportive care, the timeliness with which reversal decisions need to be made continues to demand of the emergency practitioner a familiarity with the properties and general characteristics of a variety of antithrombotic agents. Reversal options vary and may include vitamin K, FFP, PCC, rFVIIa, platelets, and desmopressin, among others.

Keywords: Anticoagulate; Antithrombotic reversal agent; Bleeding; Coagulopathic; Emergency department; Reversal options.

Publication types

Review

MeSH terms

Anticoagulants / adverse effects*
Anticoagulants / therapeutic use
Emergency Medical Services / methods*
Fibrinolytic Agents / therapeutic use*
Hemorrhage* / chemically induced
Hemorrhage* / diagnosis
Hemorrhage* / therapy
Humans

Substances

Anticoagulants
Fibrinolytic Agents